How the medical cannabis industry is transforming medicine


The medical cannabis market is set to be the largest in the world by 2020, according to a new report from the World Health Organization.

But as well as being the most profitable sector of the industry, it also faces a host of other challenges that make it a challenging area to regulate.

According to the latest edition of the WHO’s Country Reports on Drugs (CDR), which covers almost 100 countries, cannabis cultivation and distribution in Australia is the second-biggest in the region behind the US.

Cannabis is used as a therapeutic agent in treating conditions such as Crohn’s disease, epilepsy, glaucoma and cancer.

However, the vast majority of Australian consumers have no need for cannabis, with only a small proportion of adults using it recreationally.

It’s a different story in the US, where more than one in 10 people aged 16 to 64 smoke cannabis in their daily lives.

In contrast, in Australia, one in six adults aged 16-64 smoke cannabis recreationally, while about one in five adults smoke the drug recreationally every day.

The global cannabis industry was valued at $2.9 billion in 2016.

It’s expected to grow to $8.5 billion by 2020.

In Australia, about four in 10 cannabis-using adults smoke marijuana recreationally or regularly, while another four in ten do so regularly.

In 2016, about 30 per cent of the world’s population smoked cannabis recreently.

In the US it was estimated there were about 3.5 million cannabis users.

But the industry in Australia isn’t doing well.

The annual average price of cannabis is now about $600 per gram, which is 30 per 100 grams less than in the UK.

The industry has been under pressure in the last few years.

The Australian Competition and Consumer Commission (ACCC) is reviewing the rules around medical cannabis products.

The ACCC said it would look at a range of potential changes to the rules for the drug and the way it is produced and distributed.

But there’s a huge number of other issues that have been brewing for some time.

The CBD is a cannabis product with very low THC (the psychoactive ingredient) that can be used for treating conditions including Crohn’ disease, PTSD and multiple sclerosis.

However it can also be used in the treatment of a range, including multiple sclerosis, anxiety and insomnia.

A number of states, including New South Wales, Victoria and Queensland, have legalised the use of CBD products, with medicinal use also allowed.

The Federal Government last year approved the use in the management of chronic pain and chronic pain-related disorders, which are common in chronic pain sufferers.CBD has been used in other areas of medicine as well, such as neuropathic pain, post-traumatic stress disorder, and some forms of cancer.

But these are largely untested or experimental treatments.

The issue is that CBD products can be extremely potent, making them unsuitable for clinical use.

In recent years, the Australian Medical Association (AMA) has been calling for more research into the use and safety of CBD-rich cannabis products, but the Government has been reluctant to consider the possibility.

Dr Peter Lewis, the AMA’s national secretary, said the AMA was “deeply concerned about the growing use of medical cannabis in Australia and the continued lack of regulation and research”.

“This means that there is still a long way to go to bring cannabis into the mainstream,” Dr Lewis said.

“It’s time to take a more scientific approach to this important new therapeutic option.”

Dr Lewis said the growing demand for CBD-based medicines, coupled with the potential for abuse, posed a significant risk to patients.”CBD products are incredibly potent and are often very effective for certain types of pain and are therefore very addictive,” he said.

“The use of these products can cause long-term damage to the body.”

Dr Paula King, the CEO of the Australian Medicines Advisory Council, said while CBD was not yet ready for the mainstream, it was “a very promising treatment option”.

“We are seeing a lot of positive news around CBD, and we have seen some really exciting developments with CBD in the past few years,” Dr King said.

But while CBD is widely used, there are concerns around the potential dangers of using it inappropriately.

“Many people have been using CBD products inappropriately, especially for conditions such the use for anxiety or PTSD,” Dr Kingson said.

It can be difficult to tell whether someone is using CBD, or CBD products.

In November, the National Health and Medical Research Council said there was a lack of data about the safety and effectiveness of CBD, despite a growing body of evidence.

The organisation said there had been a significant increase in cannabis-related deaths in Australia in recent years.

In April, the government announced it was tightening restrictions on cannabis-based products and will introduce a mandatory five-year ban on cannabis and all CBD-derived products.

Dr King said there needed to be a stronger regulatory approach, but added the government should

cteph treatment medication

Related Posts